Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

Fig. 6

Performance of the modified E2F4 score when predicting pCR status in the Hatzis dataset. a Distribution of E2F4 activity scores based on the 33-gene signature. Vertical hashed lines indicate quantile divisions used to denote low (white), intermediate (grey), or high (dark grey) E2F4 activity. b Percentage of patients with pCR or RD that fall within the low (white), intermediate (grey) or high (dark grey) E2F4 score categories. P-value was calculated using the χ2 test. c ROC curves showing pCR classification performance when using the E2F4 scores calculated from the 33-gene signature in all (black), ER-positive (magenta), and ER-negative (aqua) patients. Grey dotted line corresponds to random classification and an AUC of 0.5

Back to article page